Related references
Note: Only part of the references are listed.Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1
Anna Makowska et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication
Yu-Yang Ng et al.
MOLECULAR THERAPY (2021)
Exploring the NK cell platform for cancer immunotherapy
Jacob A. Myers et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade
Shivani Srivastava et al.
CANCER CELL (2021)
PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures
Kathryn M. Appleton et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs
Gregory M. Cresswell et al.
CANCER RESEARCH (2021)
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer
May Daher et al.
CANCER DISCOVERY (2021)
Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β
Demi Brownlie et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
Kate J. Dixon et al.
CANCERS (2021)
Arrested development: suppression of NK cell function in the tumor microenvironment
Luke Riggan et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
Jee Hye Kang et al.
TRENDS IN IMMUNOLOGY (2021)
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
Karen Slattery et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
TAM Receptor Inhibition-Implications for Cancer and the Immune System
Pia Aehnlich et al.
CANCERS (2021)
Natural Killer Cells: From Innate to Adaptive Features
Adriana M. Mujal et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 39 (2021)
Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells
Melanie Gauthier et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Adverse events induced by immune checkpoint inhibitors
Ana Luisa Perdigoto et al.
CURRENT OPINION IN IMMUNOLOGY (2021)
TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Zhou Jiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand
Parasvi S. Patel et al.
ONCOGENE (2021)
Major Histocompatibility Complex Class I-Related Chain A (MICA) Allelic Variants Associate With Susceptibility and Prognosis of Gastric Cancer
Karen Toledo-Stuardo et al.
FRONTIERS IN IMMUNOLOGY (2021)
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies
Sigrid P. Dubois et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
Christian Sordo-Bahamonde et al.
CANCERS (2021)
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments
Olivier Demaria et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells
Hila Shaim et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
Anita K. Mehta et al.
NATURE CANCER (2021)
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients
Iva Truxova et al.
HAEMATOLOGICA (2020)
Calreticulin arms NK cells against leukemia
Jitka Fucikova et al.
ONCOIMMUNOLOGY (2020)
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Alexandra Schnell et al.
CELL RESEARCH (2020)
Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP
Yi Zhou et al.
IMMUNITY (2020)
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Kenji Chamoto et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Michael Dougan et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Regenerative lineages and immune-mediated pruning in lung cancer metastasis
Ashley M. Laughney et al.
NATURE MEDICINE (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
Hanne Lind et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade
Marcel P. Trefny et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment
Linda Borst et al.
CLINICAL CANCER RESEARCH (2020)
Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane -bound interleukin-21 expanded natural killer cells in acute myeloid leukemia
Rajeswaran Mani et al.
CYTOTHERAPY (2020)
NK Cell Function Regulation by TGF-β-Induced Epigenetic Mechanisms
Stefano Regis et al.
FRONTIERS IN IMMUNOLOGY (2020)
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Isaure Vanmeerbeek et al.
ONCOIMMUNOLOGY (2020)
Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway
John M. Idso et al.
Oncotarget (2020)
Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells
Lucas Ferrari de Andrade et al.
CANCER IMMUNOLOGY RESEARCH (2020)
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Morgane Denis et al.
FRONTIERS IN IMMUNOLOGY (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
Lihong Wang-Bishop et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Cellular cytotoxicity is a form of immunogenic cell death
Luna Minute et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics
Maryam Raeeszadeh-Sarmazdeh et al.
CELLS (2020)
NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists
Christopher J. Nicolai et al.
SCIENCE IMMUNOLOGY (2020)
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Shin Foong Ngiow et al.
FRONTIERS IN IMMUNOLOGY (2020)
Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
Nicolas Torres et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Increase of Antitumoral Effects of Cytokine-Induced Killer Cells by Antibody-Mediated Inhibition of MICA Shedding
Xiaolong Wu et al.
CANCERS (2020)
Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion
Cong He et al.
CANCERS (2020)
Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit
Bailiang Li et al.
JCI INSIGHT (2020)
Unraveling exhaustion in adaptive and conventional NK cells
Aimee M. Merino et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2020)
Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results
Anthony Goncalves et al.
CURRENT OPINION IN ONCOLOGY (2020)
Escape of tumor cells from the NK cell cytotoxic activity
Claudia Cantoni et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2020)
Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends
Jules Russick et al.
SEMINARS IN IMMUNOLOGY (2020)
The fatty-acid amide hydrolase inhibitor URB597 inhibits MICA/B shedding
Kazuma Sekiba et al.
SCIENTIFIC REPORTS (2020)
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
Chen Zhu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Re-educating Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma
Kevin X. Liu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
Ya Xu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions
Jules Russick et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade
Eduardo Bonavita et al.
IMMUNITY (2020)
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Xiao-Hui Jia et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells
Silke Eisinger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Lina Driouk et al.
FRONTIERS IN IMMUNOLOGY (2020)
Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment
Ishwar Navin et al.
CANCERS (2020)
An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma
Stefania Mantovani et al.
CANCERS (2020)
Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer
Yan Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know
Simone Camelliti et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Detection of immunogenic cell death and its relevance for cancer therapy
Jitka Fucikova et al.
CELL DEATH & DISEASE (2020)
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
Tengteng Yu et al.
BLOOD CANCER JOURNAL (2020)
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
Linda Quatrini et al.
CANCERS (2020)
An orally available non-nucleotide STING agonist with antitumor activity
Bo-Sheng Pan et al.
SCIENCE (2020)
Trial watch: STING agonists in cancer therapy
Julie Le Naour et al.
ONCOIMMUNOLOGY (2020)
The cancer-natural killer cell immunity cycle
Nicholas D. Huntington et al.
NATURE REVIEWS CANCER (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
Yumi Yokoyama et al.
CANCER RESEARCH (2019)
STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion
Chuan-xia Zhang et al.
CELL DEATH AND DIFFERENTIATION (2019)
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Lin Xiao et al.
MOLECULAR THERAPY (2019)
A Phase I/II Trial of Cetuximabin Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Elizabeth L. McMichael et al.
CLINICAL CANCER RESEARCH (2019)
Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
Kayla V. Myers et al.
MOLECULAR CANCER (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
Joseph Cursons et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
Rachael M. Zemek et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells
Dong Yang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
Beatriz Sanchez-Correa et al.
CANCERS (2019)
An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation
Luciano Castiello et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming
Aimee Merino et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Killers 2.0: NK cell therapies at the forefront of cancer control
Jonathan J. Hodgins et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells
Bin Sun et al.
CANCER IMMUNOLOGY RESEARCH (2019)
NK Cell Dysfunction and Checkpoint Immunotherapy
Jiacheng Bi et al.
FRONTIERS IN IMMUNOLOGY (2019)
MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner
Changchun Du et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
Mariya Lazarova et al.
FRONTIERS IN IMMUNOLOGY (2019)
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Thorbald van Hall et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Interleukin-18 Is a Prognostic Biomarker Correlated with CD8+ T Cell and Natural Killer Cell Infiltration in Skin Cutaneous Melanoma
Minchan Gil et al.
JOURNAL OF CLINICAL MEDICINE (2019)
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma
Haoyu Sun et al.
HEPATOLOGY (2019)
MG132 selectively upregulates MICB through the DNA damage response pathway in A549 cells
Dan Luo et al.
MOLECULAR MEDICINE REPORTS (2019)
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Fernando Souza-Fonseca-Guimaraes et al.
TRENDS IN IMMUNOLOGY (2019)
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
Hansol Lee et al.
ONCOIMMUNOLOGY (2019)
Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
Bastian J. Schmied et al.
CANCERS (2019)
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells
Jaydeep Bhat et al.
FRONTIERS IN IMMUNOLOGY (2019)
Human M2 Macrophages Limit NK Cell Effector Functions through Secretion of TGF-β and Engagement of CD85j
Sol Y. Nunez et al.
JOURNAL OF IMMUNOLOGY (2018)
NKG2D-MICA Interaction: A Paradigm Shift in Innate Recognition
Mathieu Blery et al.
JOURNAL OF IMMUNOLOGY (2018)
Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors
Sheila Lopez-Cobo et al.
ONCOIMMUNOLOGY (2018)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
Yali Han et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma
Tong Wang et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Alan Ashworth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity
Lucas Ferrari de Andrade et al.
SCIENCE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Mica-129 Dimorphism and soluble Mica are associated With the Progression of Multiple Myeloma
Alessandra Zingoni et al.
FRONTIERS IN IMMUNOLOGY (2018)
Interleukin (IL)-23 Stimulates IFN-γ Secretion by CD56bright Natural Killer Cells and Enhances IL-18-Driven Dendritic Cells Activation
Andrea Ziblat et al.
FRONTIERS IN IMMUNOLOGY (2018)
NKG2D: A Master Regulator of Immune Cell Responsiveness
Felix M. Wensveen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
Kristin C. Hicks et al.
ONCOIMMUNOLOGY (2018)
Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment
Kelong Tao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers
David L. Elion et al.
CANCER RESEARCH (2018)
NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein
Yizhou Zou et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
Estefania Paula Julia et al.
FRONTIERS IN IMMUNOLOGY (2018)
Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation
Arum Park et al.
FRONTIERS IN IMMUNOLOGY (2018)
NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy
Dominik Schmiedel et al.
FRONTIERS IN IMMUNOLOGY (2018)
Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross A. Stewart et al.
CANCER RESEARCH (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy (vol 175, pg 1014, 2018)
Matthew M. Gubin et al.
CELL (2018)
Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response
Assaf Marcus et al.
IMMUNITY (2018)
Design of amidobenzimidazole STING receptor agonists with systemic activity
Joshi M. Ramanjulu et al.
NATURE (2018)
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Stephane Champiat et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Meili Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
Kelsey E. Sivick et al.
CELL REPORTS (2018)
PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients
Fernando Concha-Benavente et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Kathleen E. Fenerty et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma
Tobias Weiss et al.
CANCER RESEARCH (2018)
NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma
Tobias Weiss et al.
CLINICAL CANCER RESEARCH (2018)
TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Hung C. Tran et al.
CLINICAL CANCER RESEARCH (2017)
Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma
Chidimma A. Nwangwu et al.
HEMATOLOGICAL ONCOLOGY (2017)
Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma
Chao Niu et al.
ONCOTARGET (2017)
High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer
Cheng Sun et al.
ONCOIMMUNOLOGY (2017)
Histone deacetylase inhibitor apicidin increases expression of the α-secretase ADAM10 through transcription factor USF1-mediated mechanisms
Xiao-Tong Hu et al.
FASEB JOURNAL (2017)
MICA-129Met/Val Polymorphism Is Associated with Early-Onset Breast Cancer Risk
Nesrine Ouni et al.
IMMUNOLOGICAL INVESTIGATIONS (2017)
TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy
Yemsratch T. Akalu et al.
IMMUNOLOGICAL REVIEWS (2017)
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
William C. Dougall et al.
IMMUNOLOGICAL REVIEWS (2017)
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Maria Carmen Ochoa et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
A Novel Fusion Antibody Exhibits Antiangiogenic Activity and Stimulates NK Cell-mediated Immune Surveillance Through Fused NKG2D Ligand
Desmond O. Acheampong et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
Y. Liu et al.
ONCOGENE (2017)
Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B
Tomoharu Miyashita et al.
ONCOLOGY LETTERS (2017)
Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function via TGFβ1 in Human Gastric Cancer
Liu-sheng Peng et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Casey R. Ager et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
Aura Muntasell et al.
FRONTIERS IN IMMUNOLOGY (2017)
Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
Christine Koch et al.
FRONTIERS IN IMMUNOLOGY (2017)
Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27
Norberto Walter Zwirner et al.
FRONTIERS IN IMMUNOLOGY (2017)
Major Histocompatibility Complex Class I Chain-Related A (MICA) Molecules: Relevance in Solid Organ Transplantation
Ajay Kumar Baranwal et al.
FRONTIERS IN IMMUNOLOGY (2017)
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Jingyu Zhang et al.
SCIENCE ADVANCES (2017)
The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3
Lulu Ni et al.
SCIENTIFIC REPORTS (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
Lekh N. Dahal et al.
CANCER RESEARCH (2017)
Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site
Takayuki Ohkuri et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue
Hormas Ghadially et al.
BRITISH JOURNAL OF CANCER (2017)
Targeting NK-cell checkpoints for cancer immunotherapy
Aura Muntasell et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients
Carolina Hager Ribeiro et al.
ONCOLOGY REPORTS (2016)
The clinical and biological significance of MICA in clear cell renal cell carcinoma patients
Xiang Zhang et al.
TUMOR BIOLOGY (2016)
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
David A. Reardon et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer
Jennifer Wu
ONCOIMMUNOLOGY (2016)
ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing
Maria Raffaella Zocchi et al.
ONCOIMMUNOLOGY (2016)
MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer
Riki Okita et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma
Mariko Tsukagoshi et al.
CANCER SCIENCE (2016)
MICA*A4 protects against ulcerative colitis, whereas MICA*A5.1 is associated with abscess formation and age of onset
A. Martinez-Chamorro et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Mattias Carlsten et al.
CLINICAL CANCER RESEARCH (2016)
Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy
Alessandra Zingoni et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2016)
Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models
Caterina Camodeca et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility
Kensuke Shiraishi et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Sebastien Viel et al.
SCIENCE SIGNALING (2016)
SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice
Mengyun Ke et al.
ONCOTARGET (2016)
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Sebastien Viel et al.
SCIENCE SIGNALING (2016)
Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment
Jeffrey L. Wong et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Impact of the MICA-129Met/Val Dimorphism on NKG2D-Mediated Biological Functions and Disease Risks
Antje Isernhagen et al.
FRONTIERS IN IMMUNOLOGY (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
TAM Receptor Signaling in Immune Homeostasis
Carla V. Rothlin et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors
Shengjun Lu et al.
CLINICAL CANCER RESEARCH (2015)
Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity
Yin-Yin Siew et al.
INTERNATIONAL IMMUNOLOGY (2015)
Big opportunities for small molecules in immuno-oncology
Jerry L. Adams et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Juan Fu et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
NKG2D Receptor and Its Ligands in Host Defense
Lewis L. Lanier
CANCER IMMUNOLOGY RESEARCH (2015)
NKG2D ligands in tumor immunity: two sides of a coin
Jinyu Zhang et al.
FRONTIERS IN IMMUNOLOGY (2015)
IL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness
Andrea Ziblat et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
Acute Antibody-Mediated Rejection in Presence of MICA-DSA and Successful Renal Re-Transplant with Negative-MICA Virtual Crossmatch
Yingzi Ming et al.
PLOS ONE (2015)
MICA, a gene contributing strong susceptibility to ankylosing spondylitis
Xiaodong Zhou et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis
Arash Nanbakhsh et al.
BLOOD (2014)
Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway
Pengfei Shi et al.
BMC CANCER (2014)
Metastatic Consequences of Immune Escape from NK Cell Cytotoxicity by Human Breast Cancer Stem Cells
Bin Wang et al.
CANCER RESEARCH (2014)
RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma
Adeline R. Lam et al.
CANCER RESEARCH (2014)
Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
Yumeng Mao et al.
CLINICAL CANCER RESEARCH (2014)
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Neha Korde et al.
HAEMATOLOGICA (2014)
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng-Ryong Woo et al.
IMMUNITY (2014)
Natural cytotoxicity receptors and their ligands
Philip H. Kruse et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention
Petra U. Prinz et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma
Zilvinas Dambrauskas et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
N-Glycosylation of Asparagine 8 Regulates Surface Expression of Major Histocompatibility Complex Class I Chain-related Protein A (MICA) Alleles Dependent on Threonine 24
Maiken Mellergaard et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma
Liang Fang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
Christopher J. Chan et al.
NATURE IMMUNOLOGY (2014)
DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization
Charlene M. Downey et al.
PLOS ONE (2014)
TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells
Sarah S. Donatelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells
Priyanka Sathe et al.
NATURE COMMUNICATIONS (2014)
A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008
Omodele Ashiru et al.
BIOCHEMICAL JOURNAL (2013)
Expansion of CD11b+Ly6G+Ly6Cint cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions
Raul German Spallanzani et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination
H. Tang et al.
GENE THERAPY (2013)
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors
Paul Spear et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the a disintegrin and metalloproteases 10 and 17
Guranda Chitadze et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis
Gang Liu et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands
Laura Jardine et al.
LEUKEMIA & LYMPHOMA (2013)
Type I interferon response and innate immune sensing of cancer
Mercedes B. Fuertes et al.
TRENDS IN IMMUNOLOGY (2013)
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis
Xinrong Ma et al.
ONCOIMMUNOLOGY (2013)
Modulation of Host Natural Killer Cell Functions in Breast Cancer via Prostaglandin E2 Receptors EP2 and EP4
Dawn M. Holt et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression
Lucas E. Rossi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Human NKG23-ligands: cell biology strategies to ensure immune recognition
Lola Fernandez-Messina et al.
FRONTIERS IN IMMUNOLOGY (2012)
Valproic Acid Upregulates NKG2D Ligand Expression through an ERK-dependent Mechanism and Potentially Enhances NK Cell-mediated Lysis of Myeloma
Xiaosong Wu et al.
NEOPLASIA (2012)
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis
Dagmar Berghuis et al.
CLINICAL SARCOMA RESEARCH (2012)
Inflammation restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation
Catharina H. M. J. Van Elssen et al.
BLOOD (2011)
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
Antonio Curti et al.
BLOOD (2011)
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Don M. Benson et al.
BLOOD (2011)
Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4
Dawn Holt et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells
Mitsugu Fujita et al.
CANCER RESEARCH (2011)
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
Yoshihiro Komohara et al.
CANCER SCIENCE (2011)
MMP9 mediates MICA shedding in human osteosarcomas
Dahui Sun et al.
CELL BIOLOGY INTERNATIONAL (2011)
Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
Maria R. Parkhurst et al.
CLINICAL CANCER RESEARCH (2011)
Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2
Yuxian Huang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Modulation of NKG2D-ligand Cell Surface Expression Enhances Immune Cell Therapy of Cancer
Baocheng Huang et al.
JOURNAL OF IMMUNOTHERAPY (2011)
HLA and MICA: Targets of Antibody-Mediated Rejection in Heart Transplantation
Qiuheng Zhang et al.
TRANSPLANTATION (2011)
Natural Killer Cell Cytotoxicity Is Suppressed by Exposure to the Human NKG2D Ligand MICA*008 That Is Shed by Tumor Cells in Exosomes
Omodele Ashiru et al.
CANCER RESEARCH (2010)
Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis
Xuzhang Lu et al.
CANCER SCIENCE (2010)
Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Laurence Zitvogel et al.
CLINICAL CANCER RESEARCH (2010)
Association analysis of MICA gene polymorphism and MICA-129 dimorphism with inflammatory bowel disease susceptibility in a Spanish population
Ruth Lopez-Hernandez et al.
HUMAN IMMUNOLOGY (2010)
ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients
Roger W. McGilvray et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Post-translational Modification of the NKG2D Ligand RAET1G Leads to Cell Surface Expression of a Glycosylphosphatidylinositol-linked Isoform
Maki Ohashi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D Ligands
Lola Fernandez-Messina et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
Jeffrey E. Rubnitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cutting Edge: The Membrane Type Matrix Metalloproteinase MMP14 Mediates Constitutive Shedding of MHC Class I Chain-Related Molecule A Independent of A Disintegrin and Metalloproteinases
Gang Liu et al.
JOURNAL OF IMMUNOLOGY (2010)
Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA
Alessandro Bressan et al.
ONCOLOGY REPORTS (2010)
Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity
Koji Yamanegi et al.
ONCOLOGY REPORTS (2010)
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
Alessandra Soriani et al.
BLOOD (2009)
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Francois Romagne et al.
BLOOD (2009)
Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis
Cai Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting
Roger W. McGilvray et al.
CLINICAL CANCER RESEARCH (2009)
Obstructing Shedding of the Immunostimulatory MHC Class I Chain-Related Gene B Prevents Tumor Formation
Jennifer D. Wu et al.
CLINICAL CANCER RESEARCH (2009)
ULBP6/RAET1L is an additional human NKG2D ligand
Robert A. Eagle et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Cutting Edge: The Metalloproteinase ADAM17/TNF-α-Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein
Philippe Boutet et al.
JOURNAL OF IMMUNOLOGY (2009)
Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-beta 1
Hequan Li et al.
JOURNAL OF IMMUNOLOGY (2009)
NKG2D Ligands Expression and NKG2D-Mediated NK Activity in Sezary Patients
Nicolas Dulphy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate
A. Poggi et al.
LEUKEMIA (2009)
Defective Infiltration of Natural Killer Cells in MICA/B-Positive Renal Cell Carcinoma Involves β2-Integrin-Mediated Interaction
Guiseppe Sconocchia et al.
NEOPLASIA (2009)
Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells
Mareike Schmudde et al.
CANCER LETTERS (2008)
Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors
Mar Vales-Gomez et al.
CANCER RESEARCH (2008)
Tumor-associated MICA is shed by ADAM proteases
Inja Waldhauer et al.
CANCER RESEARCH (2008)
Direct and natural killer cell-mediated antitumor effects of low-dose Bortezomib in hepatocellular carcinoma
Sorin Armeanu et al.
CLINICAL CANCER RESEARCH (2008)
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Nadia Guerra et al.
IMMUNITY (2008)
Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway
Beatrice Le Maux Chansac et al.
INTERNATIONAL IMMUNOLOGY (2008)
Intracellular retention of the NKG2D ligand MHC class I chain-related gene a in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity
Mercedes B. Fuertes et al.
JOURNAL OF IMMUNOLOGY (2008)
TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells
Rossana Trotta et al.
JOURNAL OF IMMUNOLOGY (2008)
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
Masahisa Jinushi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities
Stefan Diermayr et al.
BLOOD (2008)
Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells
N. Kato et al.
LEUKEMIA (2007)
Antibodies against MICA antigens and kidney-transplant rejection
Yizhou Zou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Engagement of TLR3, TLR7, and NKG2D regulate IFN-γ secretion but not NKG2D-Mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12
Maria V. Girart et al.
JOURNAL OF IMMUNOLOGY (2007)
The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection
B. Suarez-Alvarez et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity
Wei Cao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
In Vivo Expression Pattern of MICA and MICB and Its Relevance to Auto-Immunity and Cancer
Stephanie Schrambach et al.
PLOS ONE (2007)
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity
Henry Ogbomo et al.
FEBS LETTERS (2007)
Association of polymorphic extracellular domains of MICA with cervical cancer in northeastern Thai population
A. Jumnainsong et al.
TISSUE ANTIGENS (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Leveraging the immune system during chemotherapy: Moving calreticulin to the cell surface converts apoptotic death from Silent to immunogenic
Michel Obeid et al.
CANCER RESEARCH (2007)
Developmental pathways that generate natural-killer-cell diversity in mice and humans
Nicholas D. Huntington et al.
NATURE REVIEWS IMMUNOLOGY (2007)
TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells
Guenter Eisele et al.
BRAIN (2006)
ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15
Claire L. Sutherland et al.
BLOOD (2006)
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity
Masahisa Jinushi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients
NFS Watson et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Proteolytic release of soluble UL16-binding protein 2 from tumor cells
I Waldhauer et al.
CANCER RESEARCH (2006)
CD4+-CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
MJ Smyth et al.
JOURNAL OF IMMUNOLOGY (2006)
Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression
Hyunkeun Song et al.
CELLULAR IMMUNOLOGY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B
S Skov et al.
CANCER RESEARCH (2005)
CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Inhibition of NK cell activity through TGF-β1 by down-regulation of NKG2D in a murine model of head and neck cancer
S Dasgupta et al.
JOURNAL OF IMMUNOLOGY (2005)
NKG2D function protects the host from tumor initiation
MJ Smyth et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
S Gasser et al.
NATURE (2005)
TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-γ production
OM Hart et al.
JOURNAL OF IMMUNOLOGY (2005)
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo
K Wiemann et al.
JOURNAL OF IMMUNOLOGY (2005)
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
S Armeanu et al.
CANCER RESEARCH (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Effect of human cytomegalovirus on expression of MHC class I-related chains A
YZ Zou et al.
JOURNAL OF IMMUNOLOGY (2005)
Contribution of MHC class I chain-related A (MICA) gene polymorphism to genetic susceptibility for systemic lupus erythematosus
G Gambelunghe et al.
RHEUMATOLOGY (2005)
Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D
L Bacon et al.
JOURNAL OF IMMUNOLOGY (2004)
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells
S Sivori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
HR Salih et al.
BLOOD (2003)
ULBP4 is a novel ligand for human NKG2D
NJ Chalupny et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors:: Consequences for the NK-mediated killing of dendritic cells
R Castriconi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding
HR Salih et al.
JOURNAL OF IMMUNOLOGY (2002)
High frequency of MIC null haplotype (HLA-B48-MICA-del-MICB*0107 N) in the Angaite Amerindian community in Paraguay
K Aida et al.
IMMUNOGENETICS (2002)
Codominant expression of the polymorphic MICA alloantigens encoded by genes in the HLA region
LL Molinero et al.
EUROPEAN JOURNAL OF IMMUNOGENETICS (2002)
Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts
S Sumitran-Holgersson et al.
TRANSPLANTATION (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
A Cerwenka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
A Diefenbach et al.
NATURE (2001)
MICA and MICB genes:: can the enigma of their polymorphism be resolved?
HAF Stephens
TRENDS IN IMMUNOLOGY (2001)
ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
D Cosman et al.
IMMUNITY (2001)
Wide distribution of the MICA-MICB null haplotype in East Asians
M Komatsu-Wakui et al.
TISSUE ANTIGENS (2001)
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
K Imai et al.
LANCET (2000)
PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphisms are associated with psoriasis
GK Tay et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients
NW Zwirner et al.
HUMAN IMMUNOLOGY (2000)
On the MICA deleted-MICB null, HLA-B*4801 haplotype
M Ota et al.
TISSUE ANTIGENS (2000)
Share Paper
